4.20Open4.20Pre Close0 Volume606 Open Interest7.50Strike Price0.00Turnover0.00%IV0.30%PremiumOct 18, 2024Expiry Date4.19Intrinsic Value100Multiplier0DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.77Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Black Diamond Therapeutics Stock Discussion
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
Black Diamond Therapeutics (Nasdaq: BDTX) announced a corporate restructuring to focus resources on advancing its lead program BDTX-1535into pivotal development for EGFRm NSCLC. The company aims to extend its cash runway into Q2 2026. Key points include:
Anticipates sharing initial Phase 2 data for BDTX-1535 in the frontline setting for EGFRm ...
Next love, right here. 💐🥰🤫🤪
Lots of shorts returned...
No comment yet